CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $207.85M, lower than 95% of all stocks globally
- FinancialsHigh structural barrier to entry
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
207.85MUSDvs all stocks (USD)
Revenue (TTM)
36.74MUSDvs all stocks (USD)
Profit Margin
-175.78%vs Biotechnology peers
Beta
2.86xvs all stocks
52-Week Change
-30.14%vs all stocks
Market Capitalization
207.85MUSDvs all stocks (USD)
Enterprise Value
83.37MUSDvs all stocks (USD)
Forward P/E
-3.21xvs Biotechnology peers
Price to Sales (TTM)
5.66xvs Biotechnology peers
Enterprise to Revenue
2.27xvs Biotechnology peers
Enterprise to EBITDA
-1.26xvs Biotechnology peers
Profit Margin
-175.78%vs Biotechnology peers
Operating Margin
-54.78%vs Biotechnology peers
Return on Assets (TTM)
-19.92%vs Biotechnology peers
Revenue (TTM)
36.74MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.5520USDUpdated Sep 27, 2026Quarterly Revenue Growth
112.70%vs Biotechnology peers
Gross Profit (TTM)
-42.09MUSDvs all stocks (USD)
EBITDA (TTM)
-66.35MUSDvs all stocks (USD)
Net Income (TTM)
-64.58MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
112.68%vs Biotechnology peers
Operating Cash Flow (TTM)
-84.24MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-51.95MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
30.91MUSDFY2025 · Dec 31, 2025Operating Income
-82.11MUSDvs all stocks (USD)
Pre-tax Income
-74.28MUSDFY2025 · Dec 31, 2025Net Income
-74.28MUSDFY2025 · Dec 31, 2025EBIT
-82.11MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-74.49MUSDFY2025 · Dec 31, 2025Research & Development
85.47MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
27.55MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
8.74MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-74.28MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-95.15MUSDFY2025 · Dec 31, 2025Free Cash Flow
-95.20MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
84.13MUSDFY2025 · Dec 31, 2025Income Tax Paid
9.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-74.28MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.33MUSDFY2025 · Dec 31, 2025Stock-based Compensation
10.40MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.57MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
481.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-37.65MUSDFY2025 · Dec 31, 2025Capital Expenditures
-50.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-131.25MUSDFY2025 · Dec 31, 2025Sale of Investments
243.34MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
112.04MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
540.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
58.71MSharesUpdated Sep 27, 2026Float Shares
28.08MSharesUpdated Sep 27, 2026Shares Short
1.99MSharesUpdated Sep 27, 2026Short Ratio
4.88daysvs all stocks
Short % of Shares Outstanding
6.10%vs all stocks
% Held by Insiders
14.13%vs all stocks
% Held by Institutions
76.67%vs all stocks
Total Cash (MRQ)
167.58MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.82USDUpdated Sep 27, 2026Total Debt (MRQ)
43.10MUSDvs all stocks (USD)
Current Ratio (MRQ)
3.36xvs Biotechnology peers
Book Value per Share (MRQ)
-1.38USDUpdated Sep 27, 2026Total Assets
198.10MUSDvs all stocks (USD)
Total Current Assets
163.24MUSDFY2025 · Dec 31, 2025Total Liabilities
306.60MUSDFY2025 · Dec 31, 2025Total Non-current Assets
34.87MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
246.87MUSDFY2025 · Dec 31, 2025Total Current Liabilities
59.74MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
80.88MUSDFY2025 · Dec 31, 2025Other Short-term Investments
78.02MUSDFY2025 · Dec 31, 2025Accounts Payable
4.27MUSDFY2025 · Dec 31, 2025Short-term Debt
923.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
43.19MUSDFY2025 · Dec 31, 2025Other Current Liabilities
400.00KUSDFY2025 · Dec 31, 2025Long-term Debt
40.35MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
556.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-632.47MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-108.50MUSDvs all stocks (USD)
52-Week Low
3.27USDUpdated Sep 27, 202652-Week High
7.61USDUpdated Sep 27, 202652-Week Change
-30.14%vs all stocks
Beta
2.86xvs all stocks
50-Day MA
5.31USDUpdated Sep 27, 2026200-Day MA
5.08USDUpdated Sep 27, 2026Avg 10-Day Volume
532.59KSharesUpdated Sep 27, 2026Avg 30-Day Volume
438.37KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-0.9900USDUpdated Sep 27, 2026Other Income / Expense
-921.00KUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Sharp Decline With Volume And Volatility Expansion
A steep fall on heavy volume, leaving the price far below its peak.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 52.79
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $207.85M, lower than 95% of all stocks globallySignificant
Market cap (USD): 207,848,602Global P5: 275,556,405.438
Companies that share the same coordination system — how they create, deliver, or capture value.
NextBioMedical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Genomictree Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Compass Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Koa Shoji Holdings Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eledon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Humedix Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Minerva Neurosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
ImmuneOncia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sillajen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Eubiologics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Wintao Communications Co.
3 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedSharp Decline With Volume And Volatility Expansion
Goodluck India Ltd.
3 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedOperating Income Growing With Multi-Year Revenue Growth
City Retail Developments Tbk
3 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedOperating Income Growing With Multi-Year Revenue Growth